These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 23897162)
1. Mebendazole mesylate monohydrate: a new route to improve the solubility of mebendazole polymorphs. de Paula K; Camí GE; Brusau EV; Narda GE; Ellena J J Pharm Sci; 2013 Oct; 102(10):3528-38. PubMed ID: 23897162 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of a new mebendazole salt: mebendazole hydrochloride. Brusau EV; Camí GE; Narda GE; Cuffini S; Ayala AP; Ellena J J Pharm Sci; 2008 Jan; 97(1):542-52. PubMed ID: 17854049 [TBL] [Abstract][Full Text] [Related]
3. Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C. Martins FT; Neves PP; Ellena J; Camí GE; Brusau EV; Narda GE J Pharm Sci; 2009 Jul; 98(7):2336-44. PubMed ID: 18855910 [TBL] [Abstract][Full Text] [Related]
4. Characterization of solid-state forms of mebendazole. Kumar S; Chawla G; Sobhia ME; Bansal AK Pharmazie; 2008 Feb; 63(2):136-43. PubMed ID: 18380400 [TBL] [Abstract][Full Text] [Related]
5. Inclusion complexes of β-cyclodextrin and polymorphs of mebendazole: Physicochemical characterization. Saidman E; Chattah AK; Aragón L; Sancho M; Camí G; Garnero C; Longhi M Eur J Pharm Sci; 2019 Jan; 127():330-338. PubMed ID: 30445224 [TBL] [Abstract][Full Text] [Related]
6. Mebendazolium mesylate anhydride salt: rational design based on supramolecular assembly, synthesis, and solid-state characterization. Gutiérrez EL; Godoy AA; Brusau EV; Vega D; Narda GE; Suárez S; Di Salvo F RSC Adv; 2024 Jan; 14(1):181-192. PubMed ID: 38173618 [TBL] [Abstract][Full Text] [Related]
7. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Swanepoel E; Liebenberg W; Devarakonda B; de Villiers MM Pharmazie; 2003 Feb; 58(2):117-21. PubMed ID: 12641328 [TBL] [Abstract][Full Text] [Related]
8. Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole. Brits M; Liebenberg W; de Villiers MM J Pharm Sci; 2010 Mar; 99(3):1138-51. PubMed ID: 19691117 [TBL] [Abstract][Full Text] [Related]
9. Comparison of macro and micro Raman measurement for reliable quantitative analysis of pharmaceutical polymorphs. Paiva EM; da Silva VH; Poppi RJ; Pereira CF; Rohwedder JJR J Pharm Biomed Anal; 2018 Aug; 157():107-115. PubMed ID: 29787964 [TBL] [Abstract][Full Text] [Related]
10. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Swanepoel E; Liebenberg W; de Villiers MM Eur J Pharm Biopharm; 2003 May; 55(3):345-9. PubMed ID: 12754010 [TBL] [Abstract][Full Text] [Related]
11. Spherical crystallization of mebendazole to improve processability. Kumar S; Chawla G; Bansal AK Pharm Dev Technol; 2008; 13(6):559-68. PubMed ID: 18720249 [TBL] [Abstract][Full Text] [Related]
12. Analysing the crystal purity of mebendazole raw material and its stability in a suspension formulation. Agatonovic-Kustrin S; Glass BD; Mangan M; Smithson J Int J Pharm; 2008 Sep; 361(1-2):245-50. PubMed ID: 18555626 [TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis and evaluation of solid-state stability of mebendazole Forms A and C suspensions by powder X-ray diffraction using the Rietveld method. Ticona Chambi J; Deris Prado L; Ferreira de Carvalho Patricio B; Ceballos M; Bianco I; Fandaruff C; Antunes Rocha HV; Kuznetsov A; Lucia Cuffini S Int J Pharm; 2024 Jan; 650():123721. PubMed ID: 38110011 [TBL] [Abstract][Full Text] [Related]
14. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole. de Villiers MM; Terblanche RJ; Liebenberg W; Swanepoel E; Dekker TG; Song M J Pharm Biomed Anal; 2005 Jul; 38(3):435-41. PubMed ID: 15925244 [TBL] [Abstract][Full Text] [Related]
15. Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Bai RY; Staedtke V; Wanjiku T; Rudek MA; Joshi A; Gallia GL; Riggins GJ Clin Cancer Res; 2015 Aug; 21(15):3462-3470. PubMed ID: 25862759 [TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of mebendazole polymorphs in pharmaceutical raw materials using near-infrared spectroscopy. da Silva VH; Gonçalves JL; Vasconcelos FV; Pimentel MF; Pereira CF J Pharm Biomed Anal; 2015 Nov; 115():587-93. PubMed ID: 26320077 [TBL] [Abstract][Full Text] [Related]
17. Mebendazole crystal forms in tablet formulations. An ATR-FTIR/chemometrics approach to polymorph assignment. Calvo NL; Kaufman TS; Maggio RM J Pharm Biomed Anal; 2016 Apr; 122():157-65. PubMed ID: 26874854 [TBL] [Abstract][Full Text] [Related]
18. Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate. Gu CH; Gandhi RB; Tay LK; Zhou S; Raghavan K Int J Pharm; 2004 Jan; 269(1):195-202. PubMed ID: 14698591 [TBL] [Abstract][Full Text] [Related]
19. Identification of the mebendazole polymorphic form present in raw materials and tablets available in South Africa. Liebenberg W; Dekker TG; Lötter AP; de Villiers MM Drug Dev Ind Pharm; 1998 May; 24(5):485-8. PubMed ID: 9876612 [TBL] [Abstract][Full Text] [Related]
20. N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. Zimmermann SC; Tichý T; Vávra J; Dash RP; Slusher CE; Gadiano AJ; Wu Y; Jančařík A; Tenora L; Monincová L; Prchalová E; Riggins GJ; Majer P; Slusher BS; Rais R J Med Chem; 2018 May; 61(9):3918-3929. PubMed ID: 29648826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]